These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 34235925)

  • 21. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
    Lai IC; Shih PH; Yao CJ; Yeh CT; Wang-Peng J; Lui TN; Chuang SE; Hu TS; Lai TY; Lai GM
    PLoS One; 2015; 10(3):e0114830. PubMed ID: 25763821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
    Persano L; Pistollato F; Rampazzo E; Della Puppa A; Abbadi S; Frasson C; Volpin F; Indraccolo S; Scienza R; Basso G
    Cell Death Dis; 2012 Oct; 3(10):e412. PubMed ID: 23076220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
    Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
    Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells.
    Sahli F; Courcelle M; Palama T; Djaker N; Savarin P; Spadavecchia J
    J Med Chem; 2020 Jul; 63(13):7410-7421. PubMed ID: 32524814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
    Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
    Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
    Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
    Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.
    Ahmadi-Zeidabadi M; Akbarnejad Z; Esmaeeli M; Masoumi-Ardakani Y; Mohammadipoor-Ghasemabad L; Eskandary H
    Electromagn Biol Med; 2019; 38(3):198-209. PubMed ID: 31179753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
    Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
    Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
    Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
    Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
    Alafate W; Wang M; Zuo J; Wu W; Sun L; Liu C; Xie W; Wang J
    Pathol Res Pract; 2019 Nov; 215(11):152617. PubMed ID: 31563286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness.
    Jeong H; Park J; Shim JK; Lee JE; Kim NH; Kim HS; Chang JH; Yook JI; Kang SG
    J Neurooncol; 2019 May; 143(1):69-77. PubMed ID: 30887242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
    Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
    Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
    Tezcan G; Tunca B; Bekar A; Preusser M; Berghoff AS; Egeli U; Cecener G; Ricken G; Budak F; Taskapılıoglu MO; Kocaeli H; Tolunay S
    Cell Mol Neurobiol; 2014 Jul; 34(5):679-92. PubMed ID: 24691539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
    Atkins RJ; Stylli SS; Kurganovs N; Mangiola S; Nowell CJ; Ware TM; Corcoran NM; Brown DV; Kaye AH; Morokoff A; Luwor RB; Hovens CM; Mantamadiotis T
    Exp Cell Res; 2019 Jan; 374(2):353-364. PubMed ID: 30562483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.